C-Cathez® to be used in Development of Gene Therapy-Based Therapeutic by ViroMed in Korea
Mont-Saint-Guibert, Belgium, – Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of advanced regenerative therapies for heart disease, announces today that it has entered into a trade agreement with ViroMed Co., LTD for the use of Cardio3 BioSciences’ catheter C-Cathez ® in the development of ViroMed’s VM202-CAD product in Korea. Financial terms were not disclosed.
VM202-CAD is ViroMed’s gene therapy-based medicine aimed at the treatment of ischemic cardiovascular diseases via therapeutic angiogenesis. Therapeutic angiogenesis represents a novel strategy for the treatment of cardiovascular disease through the formation of new blood vessels when the therapeutic is injected into ischemic sites. A Phase I clinical study for VM202-CAD has been completed in Korea and a phase II clinical study is planned for Q4 2014.
C-Cathez ® is C3BS’ steerable percutaneous catheter. With its nitinol-based curved needle and side holes, this new generation of percutaneous injection catheter for myocardial delivery has been designed and developed to elevate the standard of care to clinicians and patients by focusing on three key features: local drug concentration, safety, and ease of use.
With C-Cathez ® , Cardio3 BioSciences provides the clinician with a catheter which can be safely steered to reach target sites within the heart left ventricle. C-Cathez ® permits stable contact with the beating myocardium without generating additional tissue trauma and diffuses the therapeutic agent over a bigger target area to obtain both a higher concentration and a wider tissue exposure.
Dr Christian Homsy, CEO of Cardio3 BioSciences, comments: “We are very glad to be able to contribute to the development of a potential new drug that aims to improve the standard of care for patients with coronary artery disease (CAD), a leading cause of death in developed countries. This is our first commercial agreement to supply C-Cathez ® and we believe it emphasizes the potential C-Cathez ® has to become a uniquely valuable tool for use with a wide array of biologics.”
Yongsoo Kim, President and CEO of ViroMed adds: “Our VM202-CAD is a novel biologic that has the potential to go beyond the limits of current treatments for ischemic cardiovascular diseases by tackling the underlying causes. Using the superbly crafted C-Cathez ® catheter in our upcoming phase II clinical study in Korea represents an important step in building the clinical evidence for our new approach to the treatment of these diseases.”